UNKL inhibitors are a class of chemical compounds that target and inhibit the activity of the protein encoded by the unkempt-like (UNKL) gene. UNKL is a ubiquitin ligase, a member of the large family of E3 ligases that play a critical role in the ubiquitin-proteasome system, a pathway essential for the regulation of protein degradation in eukaryotic cells. By catalyzing the transfer of ubiquitin molecules to specific substrates, UNKL is involved in the post-translational modification of proteins, marking them for degradation by the proteasome. The regulation of protein turnover through ubiquitination is vital for numerous cellular processes, including cell cycle regulation, signal transduction, and the maintenance of protein homeostasis. Dysregulation of ubiquitin ligases such as UNKL can result in abnormal protein accumulation or degradation, which can have profound effects on cellular function. UNKL inhibitors are designed to modulate this ligase activity, reducing or halting its ubiquitination of specific substrates.
Chemically, UNKL inhibitors may vary in structure, but they typically share characteristics that allow them to bind with high specificity to the UNKL protein, blocking its interaction with target substrates or its ability to facilitate the transfer of ubiquitin. These inhibitors are often designed through structure-based drug design, utilizing insights from the three-dimensional structure of UNKL and its active site. Once bound, these compounds can prevent the ubiquitin ligase activity of UNKL, leading to altered cellular pathways, particularly those involved in protein quality control and degradation. The discovery and synthesis of UNKL inhibitors involve intricate processes of chemical optimization, including improving the affinity of the inhibitors for their target, enhancing selectivity against other E3 ligases, and ensuring chemical stability in various experimental environments. This chemical class represents a significant area of interest in the study of protein regulation and degradation pathways.
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
PI3K inhibitor that can decrease AKT phosphorylation, affecting downstream signaling related to protein turnover. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
JNK inhibitor that can alter stress and apoptotic signaling pathways, potentially influencing proteins akin to UNKL. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
MEK inhibitor that can reduce ERK pathway activity, possibly affecting protein synthesis and degradation pathways. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
Proteasome inhibitor that can increase cellular protein levels by preventing degradation, affecting UNKL-like proteins. | ||||||
Epoxomicin | 134381-21-8 | sc-201298C sc-201298 sc-201298A sc-201298B | 50 µg 100 µg 250 µg 500 µg | $137.00 $219.00 $449.00 $506.00 | 19 | |
Selective proteasome inhibitor that can lead to accumulation of proteins, potentially affecting those similar to UNKL. | ||||||
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $31.00 $53.00 $124.00 $374.00 | 25 | |
ER-Golgi transport inhibitor that can disrupt protein trafficking, potentially impacting proteins in the same pathway as UNKL. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
mTOR inhibitor that can suppress protein synthesis, potentially affecting proteins regulated in a similar manner to UNKL. | ||||||
Cyclosporin A | 59865-13-3 | sc-3503 sc-3503-CW sc-3503A sc-3503B sc-3503C sc-3503D | 100 mg 100 mg 500 mg 10 g 25 g 100 g | $63.00 $92.00 $250.00 $485.00 $1035.00 $2141.00 | 69 | |
Calcineurin inhibitor that can modulate T-cell activation and protein phosphorylation, affecting UNKL-like pathways. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
PI3K inhibitor that can prevent AKT activation, affecting survival and growth signals connected to UNKL-like proteins. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
MEK inhibitor that can block ERK signaling, potentially impacting the regulation of UNKL-like proteins. | ||||||